ZA202507394B - Semaglutide in cardiovascular conditions - Google Patents

Semaglutide in cardiovascular conditions

Info

Publication number
ZA202507394B
ZA202507394B ZA2025/07394A ZA202507394A ZA202507394B ZA 202507394 B ZA202507394 B ZA 202507394B ZA 2025/07394 A ZA2025/07394 A ZA 2025/07394A ZA 202507394 A ZA202507394 A ZA 202507394A ZA 202507394 B ZA202507394 B ZA 202507394B
Authority
ZA
South Africa
Prior art keywords
semaglutide
cardiovascular conditions
cardiovascular
conditions
glp
Prior art date
Application number
ZA2025/07394A
Other languages
English (en)
Inventor
Oluf Kristian Højbjerg Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA202507394(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA202507394B publication Critical patent/ZA202507394B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
ZA2025/07394A 2016-04-28 2025-09-03 Semaglutide in cardiovascular conditions ZA202507394B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12

Publications (1)

Publication Number Publication Date
ZA202507394B true ZA202507394B (en) 2025-09-25

Family

ID=58668875

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2025/07394A ZA202507394B (en) 2016-04-28 2025-09-03 Semaglutide in cardiovascular conditions
ZA2025/07395A ZA202507395B (en) 2016-04-28 2025-09-03 Semaglutide in cardiovascular conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2025/07395A ZA202507395B (en) 2016-04-28 2025-09-03 Semaglutide in cardiovascular conditions

Country Status (24)

Country Link
US (3) US20190134162A1 (enExample)
EP (1) EP3448416B1 (enExample)
JP (1) JP7221694B2 (enExample)
KR (3) KR102778218B1 (enExample)
CN (1) CN109069589B (enExample)
AU (2) AU2017256774B2 (enExample)
BR (1) BR112018072020A2 (enExample)
CA (1) CA3022535A1 (enExample)
CL (1) CL2018003045A1 (enExample)
DK (1) DK3448416T3 (enExample)
ES (1) ES2928007T3 (enExample)
HR (1) HRP20221150T1 (enExample)
HU (1) HUE060040T2 (enExample)
IL (1) IL262390B1 (enExample)
MA (1) MA44762A (enExample)
MX (1) MX2018012700A (enExample)
MY (1) MY202967A (enExample)
PH (1) PH12018502274B1 (enExample)
PL (1) PL3448416T3 (enExample)
RS (1) RS63630B1 (enExample)
RU (1) RU2768283C2 (enExample)
SI (1) SI3448416T1 (enExample)
WO (1) WO2017186896A1 (enExample)
ZA (2) ZA202507394B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー／エス 安定性セマグルチド組成物およびその使用
WO2020127950A1 (en) * 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CA2797310C (en) * 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2626013T3 (es) * 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
US9085637B2 (en) * 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.

Also Published As

Publication number Publication date
RU2018140900A3 (enExample) 2020-09-28
CA3022535A1 (en) 2017-11-02
KR102778218B1 (ko) 2025-03-10
HUE060040T2 (hu) 2023-01-28
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
JP2019514925A (ja) 2019-06-06
AU2017256774A1 (en) 2018-11-01
WO2017186896A1 (en) 2017-11-02
MY202967A (en) 2024-05-31
ZA202507395B (en) 2025-09-25
EP3448416A1 (en) 2019-03-06
CN109069589A (zh) 2018-12-21
BR112018072020A2 (pt) 2019-02-12
SI3448416T1 (sl) 2022-10-28
CL2018003045A1 (es) 2018-12-14
KR20250038818A (ko) 2025-03-19
HRP20221150T1 (hr) 2022-11-25
AU2017256774B2 (en) 2024-07-11
AU2024227113A1 (en) 2024-10-31
MA44762A (fr) 2019-03-06
PL3448416T3 (pl) 2022-11-07
DK3448416T3 (da) 2022-10-03
MX2018012700A (es) 2019-01-30
ES2928007T3 (es) 2022-11-14
RS63630B1 (sr) 2022-10-31
EP3448416B1 (en) 2022-08-10
CN109069589B (zh) 2022-09-06
IL262390A (en) 2018-12-31
US20250288649A1 (en) 2025-09-18
JP7221694B2 (ja) 2023-02-14
PH12018502274A1 (en) 2019-09-09
KR20220147712A (ko) 2022-11-03
US20250262281A1 (en) 2025-08-21
RU2768283C2 (ru) 2022-03-23
KR20180135012A (ko) 2018-12-19
RU2018140900A (ru) 2020-05-28
PH12018502274B1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
ZA202507394B (en) Semaglutide in cardiovascular conditions
ZA201904616B (en) Glp-1 receptor agonists and uses thereof
MX2020014120A (es) Agonistas parciales del receptor de insulina.
MX2018005132A (es) Agonistas del receptor de glucagon.
PH12016501700A1 (en) Combination therapies with anti-cd38 antibodies
IL251027A0 (en) History of pyrrolopyrimidines as nr2b nmda receptor antagonists
WO2017100107A3 (en) Co-agonists of the glucagon and glp-1 receptors
MX2016015631A (es) Nuevos compuestos.
PH12018501844B1 (en) Liraglutide in cardiovascular conditions
PH12016500044B1 (en) Vasopressin-2 receptor agonists
GB201513543D0 (en) Compositions for use in the treatment of diabetes
UA92304U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства противодиабетического действия для терапии инсулиннезависимого сахарного диабета
PH12014000104A1 (en) Therapeutic methods and compositions for treating diabetes
IN2014CH01195A (enExample)
UA88242U (ru) Применение ралейкина (антагониста рецепторов интерлейкина-1) как средства гипогликемического действия